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The identification of radiation sensitive or resistant indivi-
duals within an apparently normal population is of potential
importance for radiotherapy, radiological protection and
detection of genetic susceptibility to cancer.
It has long been recognised that tumours of different histo-
logical types differ in radioresponsiveness. More recently, it
has become clear that there are differences in radiosensitivity
both between and within tumour classes. These are important
because small differences in radiosensitivity represent poten-
tially large differences in tumour curability after the large
cumulative doses delivered in radiotherapy. There is also a
generally held opinion that not only tumours, but apparently
normal individuals differ in their intrinsic radiosensitivity, as
evidenced by a small number of patients suffering severe
normal tissue damage following radiotherapy.
Over the past decade, more than 2,000 people have been
tested for their intrinsic cellular radiosensitivity. These
measurements have been carried out using a variety of end-
points (cell killing, cell growth delay, DNA damage/repair,
chromosome damage) and cell types (tumour, lymphocyte,
fibroblast) at a number of different centres around the world.
Many of those involved were invited to the Paterson Institute
to discuss whether there is a future for radiosensitivity test-
ing.
Tumour cells
There are two large studies measuring the radiosensitivity of
human tumours by determining surviving fraction at 2 Gy
(SF2). W. Brock (Houston) presented data obtained using
the cell adhesive matrix assay (CAM) on 140 head and neck
cancers. All the patients had been treated by surgical resec-
tion followed by post-operative radiotherapy. The average
SF2 value for patients with recurrence was higher but not
significantly different from the average SF2 value for those
without. However for oral cavity tumours there was a signi-
ficant difference.
The radiosensitivity of cervical carcinoma assessed using
the Courtenay-Mills clonogenic assay was presented by S.
Davidson and C. West (Manchester). Preliminary clinical
data on 57 patients with minimum 2 year follow-up were
shown. There was a statistically significant difference in the
mean SF2 value for tumours from 26 patients who remained
well (mean=0.40) compared with seven with recurrent
disease (mean = 0.61, P= 0.05).
E. Malaise (Paris) presented data obtained using both the
CAM and the Courtenay-Mills assays on head and neck
tumours. There was no correlation between the SF2 values
obtained for eight tumours. Possible reasons were the small
numbers studied, the wide variation of SF2 values and that
the assays were measuring different end points.
Potential methods to enhance differences between indivi-
duals are to use low dose rate or to allow for the repair of
potentially lethal damage (PLD). There is no information
available as yet using these for clinical specimens. However
both normal and malignant breast epithelial cultures show
wide variation in PLD repair (M. Gould, Madison).
E. Rofstad (Oslo) presented data from five melanoma
xenograft lines used to compare radioresponsiveness in vivo,
measured using tumour growth delay, clonogenic survival
and local tumour control as endpoints, and radiosensitivity in
vitro (clonogenic survival, SF2). Although well correlated, all
the cell lines were more radioresistant in vivo than the SF2,
measured in vitro, predicted. The reasons for this difference
may be due to regrowth between fractions rather than differ-
ences in hypoxic fraction, PLD repair or intercellular contact
effects. SF2 values for primary cultures from human tumour
specimens were shown to differ from those for cell lines
established from them suggesting that cell line data should be
interpreted with caution when compared to results from
primary culture.
There is interest in the use of short-term assays which,
although like the CAM assay these may be complicated by
the inclusion of normal cells, might produce rankings of
values similar to those obtainable using clonogenic assays.
One advantage of the MTT assay is the poor ability shown
by stromal cells to convert MTT (P. Twentyman, Cam-
bridge). A disadvantage is that sufficient time must be
allowed for untreated cells to undergo four to five doublings
(around 2 weeks for primary tumour specimens) which may
require regular cell density determinations on parallel cul-
tures. Work of J. Ramsey (Cambridge) was described on
early passage lines established from grade III and IV astro-
cytomas. The most sensitive third (n = 7) showed a statis-
tically significant difference in median survival measured in
months when compared with the most radioresistant third
(n = 7). Equivalent, although not statistically significant,
results were obtained with a clonogenic assay. It should be
noted that the MTT assay has not detected the radiosen-
sitivity of ataxia-telangiectase (A-T) lymphoblastoid lines or
of lymphoblastoid lines where sensitivity has been demon-
strated using either a clonogenic or grow-back assay (N.
Gentner, Chalk River).
Quantification of micronuclei (MN) represents an easy and
rapid test (3-4 days) which may have use as a predictive
assay. The frequency of micronucleated cells in untreated
tumours varies within and between tumour classes (C.
Streffer, Essen). Local recurrences of rectal carcinomas have
been shown to occur with a high probability in tumours with
low numbers of MN and high numbers of S-phase cells. MN
frequency may be useful for evaluation of radiosensitivity if
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measured before and during radiotherapy. A study of 26
patients with head and neck tumours (T2 and T3) determin-
ing MN formation during radiotherapy showed that for the
majority of patients alive, MN frequency increased during
treatment (after five fractions of 2 Gy).
The final session on tumours moved from intrinsic radio-
sensitivity measurements to the potential of cell kinetic
parameters to predict tumour response to radiotherapy (N.
McNally, Northwood). The parameter that appears to best
predict the capacity of a tumour to undergo accelerated
repopulation is the potential doubling time (Tpot). Pre-
liminary results from the Gray Laboratory indicate that Tpot
is not, however, a predictor of response in patients treated by
accelerated radiotherapy (CHART). Early results from a
European Organisation for Research on Treatment of Cancer
trial of accelerated fractionation suggest that it is a predictor
of failure in tumours treated by conventional fractionation.
Patients with tumours having a Tpot less than the median
did significantly better in terms of disease free survival than
those with a value greater than the median.
In summary, the promising correlations of cell and tumour
response reported to date are in the studies from Manchester,
Houston, Cambridge and Essen. These indicate that there are
measureable differences in the radiosensitivity of tumours
within a tumour class. Larger studies are required to con-
solidate the findings and more assay development is needed
to reduce the errors involved in the techniques.
Normal cells
The discovery in 1975 of the correlation between cellular
radiosensitivity of skin fibroblasts, adverse reaction to
radiotherapy and heritable cancer predisposition in A-T still
provides the basic rationale for radiosensitivity testing of
normal cells.
Colony-forming ability of fibroblasts has probably been
the most widely used assay and a 2-fold range of Do (or D)
values is obtained for the 'normal' population with increasing
evidence that there are real and reproducible differences
between individuals (C. Arlett, Brighton; J. Little, Boston).
There is a tendency for patients with disorders predisposing
to radiation-induced cancer (e.g. heritable retinoblastoma) to
exhibit responses at the lower end of the normal range. This
tendency was more clearcut for women with unusually sensi-
tive clinical responses to radiotherapy for breast cancer (J.
Little).
The colony-forming assay in fibroblasts is unsuitable for
large scale testing and so more attention is now being given
to the T-lymphocyte survival technique with which results
can be obtained within 2 weeks of taking a blood sample. In
studies on approximately 30 normal adults neither J. Cole
and C. Artlett (Brighton) nor N. Nakamura (Hiroshima)
found statistically significant differences in sensitivity between
individuals (although Cole and Arlett obtained a range of D
values from 1.26-2.15 Gy) and Nakamura found just as
much intra-(28 repeats) as inter-individual variability. In a
parallel study of fibroblast and lymphocyte survival from 26
normal individuals there was no correlation in sensitivity
between the two cell types (Cole and Arlett) suggesting that,
in spite of the precedent in A-T, the response of a single cell
type may not always be representative of the response of all
cells in an individual. More encouraging was the demonstra-
tion by Nakamura that survival curves of CD4+ and CD8+
lymphocyte subsets are very similar. Thus the use of total
lymphocytes in survival assays will not introduce bias caused
by inter-individual differences in relative proportions of
lymphocyte subsets.
If a range of genetically-determined radiation responsive-
ness exists in the 'normal' population it will include relatively
radioresistant as well as radiosensitive individuals. Nakamura
reported studies on T-lymphocyte survival assays in vitro for
183 atomic bomb survivors, 70 of whom had received doses
in excess of 1.5 Gy and the rest less than 0.5cGy. The
colony-forming abilities were very similar for the two groups
indicating that there had been no selective survival ofindivid-
uals with cellular (lymphocyte) radioresistance.
Gentner and colleagues have devised a 'growback' assay
using lymphoblastoid cell lines in which recovery from irrad-
iation is measured by cell counting at various times after
exposure. They have addressed the question of whether there
is a correlation between cellular radiosensitivity (defective
repair?) and cancer predisposition in the general population
by comparing healthy individuals with cancer patients. For
260 normal donors there was a 5-fold range in sensitivity
and, surprisingly, for 204 pre-therapy cancer patients the
distribution was skewed to lower values; the hypersensitive
group amongst normals was lacking from the cancer patients.
However, the distribution was skewed to the right relative to
normals for 59 cancer patients on or after therapy. In agree-
ment with the observation made by Little, using fibroblast
survival, some cancer patients who had exhibited adverse
treatment-related complications from conventional radio-
therapy showed hypersensitive responses.
A potentially simple and rapid alternative to cell survival/
growth assays is to measure DNA damage and repair in
freshly drawn blood samples. J. Deeley (Cardiff) reported his
experiences with nuclear lysate sedimentation and microgel
electrophoresis (the comet assay). The former was easy to
quantitate and the latter gave very quick results (within one
day) but some automated measurement of comet size is
needed. On samples from 23 healthy donors the two techni-
ques showed a reasonable agreement for the measurement of
DNA damage and repair.
In the session on chromosomal assays D. Scott (Manches-
ter) described attempts to reproduce the impressive results of
K. Sanford's group at the NCI. Using lymphocytes or fibro-
blasts irradiated in G2, Sanford et al. have reported remark-
able success in detecting defects in the repair ofx-ray induced
chromosome damage in many cancer-prone syndromes, in
'cancer families' and in about 5% of the normal population.
Using the NCI protocol in Manchester, Scott was unable to
reproduce their rapid repair kinetics in normals and found
less differential between normals and cancer-prone syn-
dromes. However, a modification of the protocol produced
NCI-type kinetics in normals and this will now be applied to
cancer-prone individuals.
Hsu and colleagues from the MD Anderson Cancer Center
have also utilised G2 lymphocytes for detection of chromo-
somal repair defects, using bleomycin rather than ionising
radiation. Hsu's extensive published results, together with his
own data, were reviewed by I. Vorechovsky (Brno). A 10-
fold range of sensitivity was shown in normal individuals
(with fairly reproducible results for any individual) and a
distinct skewing to the right for patients with various
sporadic cancers including colon, head and neck, lung and
testicular tumours. This suggests that within the general
population reduced capacity for chromsomal repair predis-
poses to cancer.
Two modifications to the standard acute irradiation proce-
dure in cytogenetic assays promise to lead to improved reso-
lution between individuals of differing repair capacity. The
first involves the use of chronic low dose rate irradiation of
Go lymphocytes (C. Roberts, Harwell) and the second utilises
a 'delayed plating' technique in stationary phase fibroblasts
with MN induction as the endpoint (Arlett). The latter tech-
nique has been shown to distinguish normals and A-T
heterozygotes and is now being used on breast cancer
patients to test the claim that between 9-18% of such
patients may be A-T heterozygotes.
In summary, there is as yet no simple routine test that
could be used on the general population for detecting differ-
ences in radiosensitivity of normal cells to predict cancer
predisposition or adverse reaction to radiotherapy although
there is increasing evidence that real differences between
individuals do exist. The most widely used and best validated
tests utilise cultured fibroblasts and are therefore slow and
expensive. Greater attention is now being given to various
lymphocyte assays and there are some promising indications
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standardised and tested in several different laboratories on a
sizeable scale with large numbers of 'normal' individuals
before being adopted for routine use.
Mechanisms
There was some discussion of possible mechanisms underly-
ing differences in radiosensitivity between cells. G. Steel
(Sutton) described the two components of ionising radiation
induced cell kill as a linear non-recoverable and a second
recoverable component. Work in his Department has shown
that both recoverable and non-recoverable damage increase
with increasing radiosensitivity i.e. that radiosensitive human
tumour cell lines are not recovery deficient. In contrast, these
studies confirm the recovery deficiency of A-T fibroblasts.
Differences between tumour lines are related to the steepness
of the linear component of cell kill and the obvious question
of interest is, what is the nature of this component? It could
perhaps be related to the production by ion clusters oflocally
multiply-damaged sites in DNA, or to the presence of hyper-
sensitive regions of the genome. Although the component is
described in G. Steel's model as non-recoverable, it should be
noted that the component is modifiable by repair inhibitors.
A technique for studying repair and misrepair at specific
sites in DNA was described (J. Thacker, Chilton) which has
shown increased misrepair in A-T cell lines. In addition to
the human genetic disorders, about eight genes controlling
radiosensitivity have been identified in cultured mammalian
cells. Around 100 yeast mutants sensitive to DNA-damaging
agents are known, and there is good homology between yeast
and human repair gene products. If there are about 100
genes involved in radiosensitivity in human cells, the fre-
quency of carriers of recessive mutant genes in an apparently
normal population would be as high as one in five. Several
human repair genes have recently been cloned, and the avail-
ability of probes to the genes and gene products offers the
prospect of a novel, direct, method for predicting radiosen-
sivity.
Clinical relevance
Parameters which are established as important in the radia-
tion response of human tumours include: histological type,
size, grade, clinical presentation and site; radiation dose level
and distribution across tumour. Variation in these para-
meters results in heterogeneity in response to radiotherapy
(H. Suit, Boston). Planning a clinical evaluation of a res-
ponse predictor would accordingly need to be based upon a
stratum of patients which is homogeneous with respect to
these parameters. Heterogeneity of response is measured by
the slope of the dose response curve ('yi). Calculations were
presented which showed that the Tm values would be :8, 2
and I for CV's of 1, 13 and ;30%. Therefore the uncertain-
ties associated with the determination of SF2 values (CV
;20% for multiple samples from one tumour) were suggest-
ed to be too large for SF2 values to be predictive for
'homogeneous' populations of tumours.
I. Turesson (Gothenberg) discussed evidence for a genetic
influence on the variability of response of normal tissues
using the clinical work in patients with carcinoma of the
breast undertaken at that centre since 1972. The endpoint
was the appearance of late skin damage in anterior chest
wall. Variations in response have been quantified and a
multifactorial analysis carried out of possible factors con-
tributing towards these differences. The factors not showing
signifcance were age, menopausal status, blood pressure,
other vascular disease, smoking, quality of radiation, chemo-
therapy or hormone therapy. Three independent prognostic
factors emerged as having some significance in determining a
late effect: (I) individual variation in dose, (2) the level of the
acute reaction, and (3) the total effect (fractionation factor
x dosage factor). Together these could account for only
around 20% of the effect. The remainder, which could possi-
ble be due to genetic effects (i.e. differences in intrinsic
radiosensitivity), is less than that predicted by the known
sensitivity of skin fibroblasts, reported above (H. Thames,
Houston).
H. Thames considered whether successful predictive assays
could give rise to therapeutic gain and if so how much gain
could be achieved. A spectrum of 'normal' radiosensitivity
was thought likely, although it was still not known whether
there was a correlation of radiosensitivity between normal
tissue and tumours of given individuals. However, improve-
ments in tumour control might be possible by identifying
subpopulations of known radiosensitivity. Alternatively the
information on radiosensitivity could be used to reduce nor-
mal tissue complications. Any procedure which helped to
generate a steeper dose response curve could be expected to
increase the chances of improving the overall result. At
present there is little clinical evidence to assist estimation of
the value of such a change although a 20% increase in
control rates for the same acceptable level of morbidity is
feasible.
General discussion
In the final summary, J. Hendry (Manchester) emphasised
the major discussion points of the Symposium. There was a
general consensus on the need to improve and develop the
available assays. The importance of obtaining a true indica-
tion of assay variability was stressed, in particular from the
aspect of multiple repeat determinations on single individuals
(as opposed to multiple assay determinations). There was a
need to establish the most relevant technique and cell type
that should be used for radiosensitivity testing, with respect
to knowledge of the mechanisms of cell death and tissue
response. A better definition of a normal range was con-
sidered to be extremely important. There was also a need for
more experiments comparing cell types (e.g. tumour/normal;
lymphocyte/fibroblast) within the same individual. Ways of
increasing the magnitude of differences between individuals
were promoted (e.g. using low dose rate). The importance of
radiosensitivity measurements within a multivariate analysis
in radiotherapy was stressed throughout. In particular com-
bining radiosensitivity measurements with a measure of
tumour proliferation was felt likely to increase the prob-
ability of predicting treatment response.
In a vote, all of those attending the meeting considered
there was a future for radiosensitivity testing in general while
around 75% considered there was a future within radio-
therapy. Whether the techniques used at present will continue
to be used remains to be seen. There was a general consensus
that the area of work was exciting, that there was con-
siderable scope for expansion and some hope that it might in
the long term prove to be of value for routine evaluation of
radiosensitivity.
Reported by C.M.L. West, J.H. Hendry, D. Scott, S.E.
Davidson, and R.D. Hunter.
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